Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Cian expects to close its acquisition of SmartDeal by the end of the year

8/17/23 CIAN

Cherkizovo reported 6 months of 2023 by IFRS

8/17/23 GCHE

Rosgosstrakh reported for 6 months of 2023 by IFRS

8/17/23 RGSS

En+ Group reported for 6 months of 2023 by IFRS

8/17/23 ENPG

Issuers hope for extension of moratorium on delisting of quasi-Russian securities

8/17/23 MOEX

Cisco reported for fiscal year 2023

8/17/23 CSCO

Qiwi assessed the impact of the Bank of Russia's restrictions on its business

8/17/23 QIWI

The Cisco Systems announced a quarterly dividend

8/16/23 CSCO

QIWI reported for 6 months of 2023

8/16/23 QIWI

Globaltrans shareholders approved the redomiciliation from Cyprus to Abu Dhabi

8/16/23 GLTR